» Articles » PMID: 35117557

Co-existence of Myeloproliferative Neoplasias and β-thalassemia with IVS-2-654 Mutation-a Case Report

Overview
Specialty Oncology
Date 2022 Feb 4
PMID 35117557
Authors
Affiliations
Soon will be listed here.
Abstract

Thalassemia and myeloproliferative neoplasias (MPNs) are recognized as two separate diseases. Thalassemia is a hemolytic disease caused by abnormal goblin genes, which results in the deficiency of globin chains. MPNs are clonal hematopoietic stem cell diseases characterized by the proliferation of multiple myeloid lineages. The coexistence of thalassemia and myeloproliferative neoplasia are rarely reported. We herein describe a case of a 24-year-old woman, previously diagnosed as β-thalassemia, with a lifelong history of thrombocytosis. She was subsequently diagnosed as low-risk essential thrombocythemia (ET), one of the MPNs. The patient was treated with folic acid supplementation and Iron-chelating therapy, without aspirin or cytoreductive therapy. Up to date, no thrombotic events or disease-related bleeding are happening to the patient, who remains in good health. Furthermore, we found three novel genes mutations EP300, CUX1, and FGFR3 after next-generation sequencing. We presume that the mutations of these genes in β-thalassemia might have an impact on the happening of ET and therefore need further investigations.

Citing Articles

Autosomal Recessive Hyper-IgE Syndrome in a Child With Beta Thalassemia Trait: A Case Report.

Linganagouda S, Jadhav R, Verma S, Bharaswadkar R Cureus. 2024; 16(6):e61864.

PMID: 38978914 PMC: 11228417. DOI: 10.7759/cureus.61864.


Negative regulation of expression through S6K by long noncoding RNA NR_120526.

Jia W, Wu X, Chen Z, Lin W, He Y Transl Pediatr. 2023; 12(5):907-917.

PMID: 37305725 PMC: 10248940. DOI: 10.21037/tp-23-174.


Acute Promyelocytic Leukemia in a Woman with Thalassemia Intermedia: Case Report and Review of Literature on Hematological Malignancies in β-Thalassemia Patients.

Pellegrino C, Dragonetti G, Chiusolo P, Rossi M, Orlando N, Teofili L Hematol Rep. 2022; 14(4):310-321.

PMID: 36278522 PMC: 9590045. DOI: 10.3390/hematolrep14040045.

References
1.
Martinez-Lopez J, Jimenez A, Sanchez-Calero J, Monteagudo D, Urbanowicz M, Canamares-Orbis I . Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. Ann Hematol. 2015; 94(7):1237-9. DOI: 10.1007/s00277-015-2352-9. View

2.
Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

3.
Higgs D, Engel J, Stamatoyannopoulos G . Thalassaemia. Lancet. 2011; 379(9813):373-83. DOI: 10.1016/S0140-6736(11)60283-3. View

4.
Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K . Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011; 118(1):167-76. DOI: 10.1182/blood-2011-01-331678. View

5.
Bryan E, Jokubaitis V, Chamberlain N, Baxter S, Dawson E, Choong D . Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer. 2002; 102(2):137-41. DOI: 10.1002/ijc.10682. View